COMMUNIQUÉS West-GlobeNewswire

MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
03/10/2024
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure [...]
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
03/10/2024
The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024 The collaboration supports Teva's Pivot to Growth strategy and adds to the company’s [...]
NMS Capital Portfolio Company Surplus Solutions Expands Internationally; Announces Partnership with FAMECO Group ApS
03/10/2024
NEW YORK and STRASBOURG, France, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Surplus Solutions LLC (“Surplus Solutions”), a portfolio company of NMS Capital (“NMS”), announced today that it has expanded internationally via a [...]
Spectral AI Completes Proof of Concept for Wound Measurement Technology
03/10/2024
Provides Clinicians with Superior Wound Size Measurement Information that Improves Patient Treatment Decisions DALLAS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company [...]
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
03/10/2024
-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ [...]
Monthly information on share capital and company voting rights
02/10/2024
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
02/10/2024
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 02 oct. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy
02/10/2024
Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
02/10/2024
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
Globus Medical Launches the Next Wave of Orthopedic Trauma Solutions
02/10/2024
AUDUBON, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, announces the continued growth and expansion of its orthopedic trauma product portfolio. [...]
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
WALTHAM, Mass. and DUBLIN, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to [...]
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2024
CHARLESTOWN, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]
Certara Completes Acquisition of Chemaxon
02/10/2024
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization. RADNOR, Pa., [...]
BriaCell Therapeutics Announces Closing of $5 Million Offering
02/10/2024
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company
02/10/2024
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, [...]
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
02/10/2024
TuHURA has extended their exclusivity and right of first offer pursuant to the terms of the agreement. Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid [...]
Range Impact Announces Sale of Cannabinoid Drug Development Business
02/10/2024
CLEVELAND, OHIO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to improving the health and wellness of people and the planet through a [...]

Pages